Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza

Lentiviral-mediated expression of monoclonal antibodies in the lung to protect against influenza

Bibliographic Details
Main Authors:	Du, Y, Munday, RJ, Tan, TK, Rijal, P, Townsend, AR, Hyde, SC, Gill, DR
Format:	Conference item
Language:	English
Published:	Cell Press 2020

Similar Items

Lung-targeting lentiviral vector for passive immunisation against influenza
by: Tan, TK, et al.
Published: (2020)

Lung-targeted lentiviral vector mediates passive immunisation against influenza
by: Tan, T, et al.
Published: (2018)

431. Lung antibody factory for passive immunisation against influenza
by: Tan, T, et al.
Published: (2016)

Investigating pseudotyped lentiviral vectors for gene delivery to the lung
by: Munday, RJ
Published: (2021)

Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza
by: Zuleika Michelini, et al.
Published: (2020-12-01)

High levels of native eGFP detected following F/HN lentiviral vector transduction of a variety of lung models
by: Munday, R, et al.
Published: (2019)

A method for assessing the distribution of eGFP expressing cells in the mouse lung following lentiviral vector transduction
by: Munday, R, et al.
Published: (2018)

Lentiviral vector pseudotyped with sendai virus F and HN proteins uses sialylated glycan receptors to efficiently target human airway cells
by: Munday, RJ, et al.
Published: (2020)

F/HN pseudotyped lentiviral vector uses alpha 2,3 sialylated N-acetyllactosamine to efficiently transduce human airway cells
by: Munday, RJ, et al.
Published: (2022)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
by: Munday, RJ, et al.
Published: (2022)

Broadly inhibiting antineuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans
by: Rijal, P, et al.
Published: (2020)

Development of lung and muscle protein factories to deliver therapeutic monoclonal antibodies
by: Antepowicz, A, et al.
Published: (2016)

A study of human monoclonal antibodies to influenza and ebola viruses
by: Rijal, P
Published: (2016)

Rapid determination of rSIV.F/HN lentiviral vector titre
by: Conway, CC, et al.
Published: (2020)

A direct contact pig influenza challenge model for assessing protective efficacy of monoclonal antibodies
by: Adam McNee, et al.
Published: (2023-10-01)

Use of pseudotyped, replication deficient influenza to facilitate testing of gene delivery strategies for treatment of highly infectious diseases
by: Tan, T, et al.
Published: (2018)

Correction: Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans
by: Barbara Holzer, et al.
Published: (2021-08-01)

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans
by: Rijal, P, et al.
Published: (2019)

Intranasal lentiviral vector-mediated antibody delivery confers reduction of SARS-CoV-2 infection in elderly and immunocompromised mice
by: Du, Y, et al.
Published: (2022)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Antepowicz, A, et al.
Published: (2021)

Enhanced lentiviral production through rational design of mammalian host cells
by: Hyde, S, et al.
Published: (2016)

Cholesterol as an enhancer of lentiviral vector production in serum-free transient transfection
by: Gelinas, J, et al.
Published: (2013)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
by: Agata Antepowicz, et al.
Published: (2021-08-01)

Passive immunization with influenza haemagglutinin specific monoclonal antibodies
by: Rajeev Rudraraju, et al.
Published: (2018-11-01)

Broadly Protective Neuraminidase-Based Influenza Vaccines and Monoclonal Antibodies: Target Epitopes and Mechanisms of Action
by: Nada Abbadi, et al.
Published: (2023-01-01)

Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.
by: Taia T Wang, et al.
Published: (2010-02-01)

Protective efficacy of anti-neuraminidase monoclonal antibodies against H7N9 influenza virus infection
by: Fei-Fei Xiong, et al.
Published: (2020-01-01)

Protective monoclonal antibodies to diphtheria toxin
by: Maria das Graças M. Danelli, et al.
Published: (1991-06-01)

Assessment of selected media supplements to improve F/HN lentiviral vector production yields
by: Gélinas, J, et al.
Published: (2017)

Mucosal immunization with integrase-defective lentiviral vectors protects against influenza virus challenge in mice.
by: Judith M Fontana, et al.
Published: (2014-01-01)

Human monoclonal antibodies broadly neutralizing against influenza B virus.
by: Mayo Yasugi, et al.
Published: (2013-02-01)

Antibody immunoprophylaxis and immunotherapy for influenza virus infection: Utilization of monoclonal or polyclonal antibodies?
by: Cassandra M. Berry
Published: (2018-03-01)

Monoclonal antibodies targeting the influenza virus N6 neuraminidase
by: Shirin Strohmeier, et al.
Published: (2022-07-01)

Hemagglutination Inhibition (HI) Assay of Influenza Viruses with Monoclonal Antibodies
by: Ying Wu, et al.
Published: (2016-06-01)

Micro Neutralization (MN) Assay of Influenza Viruses with Monoclonal Antibodies
by: Ying Wu, et al.
Published: (2016-06-01)

Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors
by: Rosie J. Munday, et al.
Published: (2022-09-01)

Human monoclonal antibodies from convalescent H7N9 patients in China and Taiwan
by: Rijal, P, et al.
Published: (2014)

Large-scale, high-throughput production of lentiviral vectors for multiple disease applications
by: Ashworth, R, et al.
Published: (2018)

Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola
by: Tan, T, et al.
Published: (2017)

A pan-influenza monoclonal antibody neutralizes H5 strains and prophylactically protects through intranasal administration
by: Anna L. Beukenhorst, et al.
Published: (2024-02-01)